![](https://ml.globenewswire.com/media/de42834e-6ecd-4cbb-ae4c-c4a7cbdb1dbd/medium/figure-1.png)
Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter baumannii
RECCE® 327 (R327) demonstrated significant bactericidal activity against ‘superbug’ Acinetobacter baumannii (A. baumannii) demonstrating 99.99999% log reduction (>7.5 log reduction) in adult human epidermal ‘skin’ cells A. baumannii is most commonly …